Latest Biologic Stories
Exclusive Licensing Agreement for CAR T Cell, TCR, NK Cell Programs and Associated Technologies for the Development of Non-Viral Adoptive Cellular Therapies GERMANTOWN, Md., BOSTON,
LAKE FOREST, Ill., Jan.
Selexis SA announced today the first therapeutic biologic generated with the Selexis SUREtechnology Platform™ has been approved for market. Geneva, Switzerland
BEIJING, Jan. 8, 2015 /PRNewswire/ -- China Biologic Products, Inc.
Moderna venture to advance mRNA vaccines and mRNA-based passive immunity therapies CAMBRIDGE, Mass., Jan.
Today, NCPDP addressed the FDA, CDER and ODAC meeting that met to review and make a recommendation on what may be the first biosimilar to receive FDA approval in the U.S., and potentially develop
LONDON, Jan. 7, 2015 /PRNewswire/ -- About Psoriasis and Its TypesPsoriasis is a common immune-mediated disease of the skin.
ROCKVILLE, Md., Jan.
CAMBRIDGE, England, January 6, 2015 /PRNewswire/ -- Crescendo Biologics, a company focused on the discovery and development of best-in-class Humabody(TM) human VH antibody
Represents a Novel Approach to Treating B-cell Lymphoma in Dogs KANSAS CITY, Kan., Jan.
- Large; stout; burly.